Successful management of bilateral orbital metastases from invasive lobular breast cancer with abemaciclib and letrozole: a case report and literature review

Successful management of bilateral orbital metastases from invasive lobular breast cancer with abemaciclib and letrozole: a case report and literature review

Breast cancer is a significant global health concern, contributing to substantial morbidity and mortality among women. Hormone receptor-positive (HR+)/HER2-negative (HER2-) breast cancer constitutes a considerable proportion of cases, and significant advancements have been made in its management. CD...

Full description

Bibliographic Details
Main Authors:	Nuno Rodrigues Alves, Ana Filipa Duarte, David Fernandes Ribeiro, Rita Sousa Silva, Bruno Almeida Carvalho, Diogo Alpuim Costa
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-01-01
Series:	Frontiers in Oncology
Subjects:	CDK4/6 inhibitor abemaciclib letrozole breast cancer orbit metastases
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1286910/full

Similar Items

The effectiveness of hyperbaric oxygen therapy for managing radiation-induced proctitis – results of a 10-year retrospective cohort study
by: António Moreira Monteiro, et al.
Published: (2023-08-01)

Case report: Primary CDK4/6 inhibitor and endocrine therapy in locally advanced breast cancer and its effect on gut and intratumoral microbiota
by: Guilherme Vilhais, et al.
Published: (2024-03-01)

Relapsing eosinophilic pneumonia in a patient with recurrent breast cancer receiving abemaciclib plus endocrine therapy
by: Hiroaki Ogata, et al.
Published: (2024-03-01)

Hyperbaric oxygen therapy as a complementary treatment in neuroblastoma — a narrative review
by: Diogo Alpuim Costa, et al.
Published: (2023-09-01)

Anthracyclines and trastuzumab associated cardiotoxicity: is the gut microbiota a friend or foe? – a mini-review
by: J. Guilherme Gonçalves-Nobre, et al.
Published: (2023-09-01)

Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment
by: Lu Turković, et al.
Published: (2022-05-01)

Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib
by: Flavia Jacobs, et al.
Published: (2023-02-01)

Mutation Patterns in Portuguese Families with Hereditary Breast and Ovarian Cancer Syndrome
by: Rodrigo Vicente, et al.
Published: (2022-09-01)

Evaluating the Effects of Molecular Dynamic And Docking of Abemaciclib, Hymenialdisine, and Indirubin on CDK-2 Inhibition by Simulation Study
by: Majid Asadi-Samani, et al.
Published: (2022-03-01)

The potential links between human gut microbiota and cardiovascular health and disease - is there a gut-cardiovascular axis?
by: Cátia Almeida, et al.
Published: (2023-10-01)

Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer
by: Panagiotis A. Konstantinopoulos, et al.
Published: (2024-04-01)

Efficiency and tolerability of abemaciclib in elderly patients
by: E. I. Kovalenko, et al.
Published: (2020-12-01)

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
by: Chao-Yue Sun, et al.
Published: (2022-06-01)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
by: Zhimin Zhu, et al.
Published: (2023-07-01)

Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center
by: Dominik Dannehl, et al.
Published: (2022-03-01)

Hyperbaric Oxygen Therapy as a Complementary Treatment for Osteoradionecrosis of the Mandible: Useless or Useful? - A Literature Review
by: Diogo Alpuim Costa, et al.
Published: (2024-02-01)

Rapid Capillary Electrophoresis Method for Simultaneous Determination of Abemaciclib, Ribociclib, and Palbociclib in Pharmaceutical Dosage Forms: A Green Approach
by: Zvonimir Mlinarić, et al.
Published: (2022-11-01)

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review
by: Yan Mao, et al.
Published: (2023-01-01)

Local Breast Microbiota: A “New” Player on the Block
by: Marina Vitorino, et al.
Published: (2022-08-01)

Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: A case report and literature review
by: Zhaohui Chu
Published: (2022-11-01)

Clinical Experience with Abemaciclib in Patients Previously Treated with Another CDK 4/6 Inhibitor in a Tertiary Hospital: A Case Series Study
by: Alicia Milagros de Luna Aguilar, et al.
Published: (2023-09-01)

Gut microbiota profile of COVID-19 patients: Prognosis and risk stratification (MicroCOVID-19 study)
by: José Guilherme Nobre, et al.
Published: (2022-11-01)

Tyrosine Kinase Inhibitors - Induced Cutaneous Leukocytoclastic Vasculitis
by: Diogo Alpuim Costa, et al.
Published: (2018-05-01)

Hematological Events Potentially Associated with CDK4/6 Inhibitors: An Analysis from the European Spontaneous Adverse Event Reporting System
by: Vera Martins, et al.
Published: (2023-09-01)

Breast Cancer Survivors and Healthy Women: Could Gut Microbiota Make a Difference?—“BiotaCancerSurvivors”: A Case-Control Study
by: Telma Caleça, et al.
Published: (2023-01-01)

Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas
by: Muh-Lii Liang, et al.
Published: (2020-12-01)

Evolution of the CDK4/6 inhibitor abemaciclib: from palliative to adjuvant therapy. Clinical experience with abemaciclib in patients with hormone-receptor-positive, HER2-negative breast cancer
by: A. Yu. Goryainova, et al.
Published: (2022-06-01)

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review
by: Ioana-Miruna Stanciu, et al.
Published: (2023-04-01)

Effect of Letrozole on Eye Development in Rat Embryos
by: M Mahmoudi, et al.
Published: (2015-03-01)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
by: Silvia La Monica, et al.
Published: (2020-12-01)

Comprehensive Genomic Profiling of Cell-Free Circulating Tumor DNA Detects Response to Ribociclib Plus Letrozole in a Patient with Metastatic Breast Cancer
by: Catarina Silveira, et al.
Published: (2022-12-01)

Development of a SPE-LC-MS Method for the Quantitation of Palbociclib and Abemaciclib in Human Plasma
by: Daniela Maria Calucică, et al.
Published: (2022-12-01)

Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story
by: Vittorio Gebbia
Published: (2023-04-01)

Letrozole and Ovarian Hyperstimulation Syndrome (OHSS): A Promising Prevention Strategy
by: Federica Di Guardo, et al.
Published: (2023-01-01)

CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
by: Rita Terenziani, et al.
Published: (2022-11-01)

The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models [Letter]
by: Wardoyo S, et al.
Published: (2023-12-01)

The Potent Novel CDK4/6 Inhibitor TQB3616 in Hormone Receptor Positive Breast Cancer: Preclinical Characterization with in vitro and Human Tumor Xenograft Models
by: Hu W, et al.
Published: (2023-12-01)

Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant
by: Ernest H Law, et al.
Published: (2023-04-01)

Development and in vitro evaluation of Letrozole loaded biodegradable nanoparticles for breast cancer therapy
by: Sanjoy Kumar Dey, et al.
Published: (2009-09-01)

Angioneurotic edema of metastatic breast cancer patient associated with letrozole
by: Yasemin Bakkal Temi, et al.
Published: (2017-12-01)